Comparison Overview

Grifols

VS

The Janssen Pharmaceutical Companies of Johnson & Johnson

Grifols

Parc Empresarial Can Sant Joan, Av. de la Generalitat, 152-158, Sant Cugat del Vallès, Barcelona, ES, 08174
Last Update: 2025-12-17
Between 750 and 799

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2025, Grifols was named one of TIME’s ‘World’s Best Companies’ for the third year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best World Employers 2025," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,388
Subsidiaries: 4
12-month incidents
0
Known data breaches
0
Attack type number
0

The Janssen Pharmaceutical Companies of Johnson & Johnson

1000 U.S. Highway 202, Raritan, New Jersey, US
Last Update: 2025-12-17
Between 750 and 799

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension. Visit us: www.janssen.com Follow us: @JanssenGlobal on Twitter and Instagram Watch our videos on our YouTube channel: http://bit.ly/1LY2xQ5

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,253
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/grifols.jpeg
Grifols
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/janssen-pharmaceutical-companies-of-johnson-and-johnson.jpeg
The Janssen Pharmaceutical Companies of Johnson & Johnson
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Grifols
100%
Compliance Rate
0/4 Standards Verified
The Janssen Pharmaceutical Companies of Johnson & Johnson
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Grifols in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for The Janssen Pharmaceutical Companies of Johnson & Johnson in 2025.

Incident History — Grifols (X = Date, Y = Severity)

Grifols cyber incidents detection timeline including parent company and subsidiaries

Incident History — The Janssen Pharmaceutical Companies of Johnson & Johnson (X = Date, Y = Severity)

The Janssen Pharmaceutical Companies of Johnson & Johnson cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/grifols.jpeg
Grifols
Incidents

No Incident

https://images.rankiteo.com/companyimages/janssen-pharmaceutical-companies-of-johnson-and-johnson.jpeg
The Janssen Pharmaceutical Companies of Johnson & Johnson
Incidents

No Incident

FAQ

The Janssen Pharmaceutical Companies of Johnson & Johnson company demonstrates a stronger AI Cybersecurity Score compared to Grifols company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, The Janssen Pharmaceutical Companies of Johnson & Johnson company has disclosed a higher number of cyber incidents compared to Grifols company.

In the current year, The Janssen Pharmaceutical Companies of Johnson & Johnson company and Grifols company have not reported any cyber incidents.

Neither The Janssen Pharmaceutical Companies of Johnson & Johnson company nor Grifols company has reported experiencing a ransomware attack publicly.

Neither The Janssen Pharmaceutical Companies of Johnson & Johnson company nor Grifols company has reported experiencing a data breach publicly.

Neither The Janssen Pharmaceutical Companies of Johnson & Johnson company nor Grifols company has reported experiencing targeted cyberattacks publicly.

Neither Grifols company nor The Janssen Pharmaceutical Companies of Johnson & Johnson company has reported experiencing or disclosing vulnerabilities publicly.

Neither Grifols nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds any compliance certifications.

Neither company holds any compliance certifications.

Grifols company has more subsidiaries worldwide compared to The Janssen Pharmaceutical Companies of Johnson & Johnson company.

The Janssen Pharmaceutical Companies of Johnson & Johnson company employs more people globally than Grifols company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Grifols nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds SOC 2 Type 1 certification.

Neither Grifols nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds SOC 2 Type 2 certification.

Neither Grifols nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds ISO 27001 certification.

Neither Grifols nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds PCI DSS certification.

Neither Grifols nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds HIPAA certification.

Neither Grifols nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A vulnerability has been found in SeaCMS up to 13.3. The affected element is an unknown function of the file js/player/dmplayer/dmku/class/mysqli.class.php. Such manipulation of the argument page/limit leads to sql injection. The attack can be executed remotely. The exploit has been disclosed to the public and may be used.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in HappyDevs TempTool allows Stored XSS.This issue affects TempTool: from n/a through 1.3.1.

Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in Tormorten WP Microdata allows Stored XSS.This issue affects WP Microdata: from n/a through 1.0.

Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
Description

Exposure of Sensitive System Information to an Unauthorized Control Sphere vulnerability in HappyDevs TempTool allows Retrieve Embedded Sensitive Data.This issue affects TempTool: from n/a through 1.3.1.

Risk Information
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
Description

A vulnerability has been found in Tenda FH1201 1.2.0.14(408). Affected is the function sprintf of the file /goform/SetIpBind. Such manipulation of the argument page leads to stack-based buffer overflow. The attack may be performed from remote. The exploit has been disclosed to the public and may be used.

Risk Information
cvss2
Base: 9.0
Severity: LOW
AV:N/AC:L/Au:S/C:C/I:C/A:C
cvss3
Base: 8.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
cvss4
Base: 7.4
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X